Voyager Acquisition Corp.
VACH.US | Activities of holding companies
Voyager Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the company may pursue an initial business combination target in any i...Show More
Better Health for All
20
VERAXA Biotech AG, the company being acquired by Voyager Acquisition Corp., is entirely focused on developing next-generation cancer therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, aiming for superior efficacy and reduced side effects.
1
This dedication to treating severe diseases means its entire business is devoted to health improvement. The company's VX-A901 program, a FLT3-targeting antibody, demonstrated safety and tolerability in a Phase 1 clinical trial involving 31 AML patients.
2
While the company's VX-A901 program targets elderly AML patients, which is a vulnerable population, there is no specific data on the *extent* to which this population obtains equitable access.
3
There is no evidence of revenue from products with negative health outcomes, as the company is focused on developing new therapies.
4
Fair Money & Economic Opportunity
0
No evidence available to assess Voyager Acquisition Corp on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
VACH.US is a blank check company, and the provided evidence explicitly states that all worker-related metrics, including living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, and health insurance coverage, are not applicable to its current structure and operations.
1
Fair Trade & Ethical Sourcing
0
Voyager Acquisition Corp (VACH.US) is a blank check company formed for the purpose of effecting a business combination. As such, it does not currently have operational supply chain activities, procure physical commodities, or have a supplier base. Therefore, all KPIs related to fair trade and ethical sourcing are not applicable.
1
No evidence regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk, or supplier diversity spend for VACH.US was found in the provided articles.
2
Information pertaining to 'Voyager Coffee' is not relevant to VACH.US.
Honest & Fair Business
0
No evidence available to assess Voyager Acquisition Corp on Honest & Fair Business.
Kind to Animals
-40
VERAXA Biotech, which has a business combination agreement with Voyager Acquisition Corp., uses Quadira Biosciences AG's proprietary 3D CoSeedis™ technology platform for the replication and modelling of human tissue for testing and characterization of antibodies without animal testing.
1
However, VERAXA's Code of Conduct, adopted on January 15, 2024, states, "We avoid testing on animals when we can, although sometimes this is unavoidable."
2
VERAXA is also responsible for preclinical validation of a bsADC lead candidate, and its co-discovery alliance partner, OmniAb, Inc., utilizes transgenic antibody discovery solutions that source human antibody leads through in vivo affinity maturation.
3
VERAXA is a member of an industry consortium (OmniAb, Inc.) working on animal-free testing methods, but the evidence does not specify the extent of its contributions.
No War, No Weapons
-70
Voyager Technologies is expanding its dual-use technology portfolio, with its propulsion technology used in both military applications, such as missile defense and strategic/tactical/hypersonic missiles, and civilian/commercial space launch systems.
1
The company's core business involves producing energetics, propulsion systems, and mission-critical components for missile defense and tactical munitions.
2
There is no evidence of civilian safeguards, contractual bars on military applications, or any screening processes for dual-use technologies. Furthermore, the company plans to integrate AI-enabled supply chain management into its defense complex,
3
but there is no mention of ethical safeguards for these AI systems with potential military uses.
Planet-Friendly Business
0
The provided articles focus on the business combination between Voyager Acquisition Corp. and VERAXA Biotech AG, detailing financial aspects, market projections, and VERAXA's oncology pipeline. No specific data or information regarding environmental performance, climate targets, resource consumption, waste management, or any other planet-friendly business metrics for either company was found.
1
Therefore, no KPIs could be scored based on the available evidence.
Respect for Cultures & Communities
0
No specific, quantitative evidence regarding VACH.US's performance on 'Respect for Cultures & Communities' was found in the provided articles.
1
All articles were placeholders and explicitly stated a lack of relevant data for any of the defined KPIs.
2
Safe & Smart Tech
0
VACH.US is a blank check company. The provided articles refer to 'Voyager Portal' and 'Voyager Worldwide', detailing a SOC 2 Type II certification for 'Voyager Portal'.
1
and a cyber incident for 'Voyager Fleet Insight' (a platform of 'Voyager Worldwide').
2
However, none of the articles explicitly state that 'Voyager Portal' or 'Voyager Worldwide' are VACH.US, or that VACH.US has completed an acquisition or merger with these entities. Therefore, no specific, concrete data points can be attributed to VACH.US, and no KPIs can be scored.
Zero Waste & Sustainable Products
0
No specific, quantitative, or qualitative evidence was found in the provided articles regarding VACH.US's (or its future merged entity Veraxa Biotech's) performance on any of the 'Zero Waste & Sustainable Products' KPIs. The articles primarily discuss the financial details of the merger between Voyager Acquisition Corp and Veraxa Biotech, Veraxa's product pipeline, or general sustainability trends and best practices within the healthcare and pharmaceutical industries, without providing company-specific data for VACH.US or Veraxa.